GeoVax Labs, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GeoVax Labs, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.46M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($24.99M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($25.97M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.02M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($18.57M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($2.96M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($2.37M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($2.56M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($2.17M) | Mar 26, 2019 |
| FY2018 | Dec 31, 2016 | ($3.27M) | Mar 26, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.64M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($25.14M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($26.74M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.03M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($18.75M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($2.82M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($2.37M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($2.56M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($2.17M) | Mar 26, 2019 |
| FY2018 | Dec 31, 2016 | ($3.27M) | Mar 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.12M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $23.71M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $20.72M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $9.12M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $15.55M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.44M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $1.91M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.88M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $2.02M | Mar 26, 2019 |
| FY2018 | Dec 31, 2016 | $1.97M | Mar 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.47M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($24.68M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($25.17M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($19.03M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($11.20M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($2.75M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($1.40M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($1.54M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($1.69M) | Mar 26, 2019 |
| FY2018 | Dec 31, 2016 | ($1.95M) | Mar 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.6K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $20.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $48.9K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $134.3K | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $47.7K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $156.8K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $7.6K | Mar 23, 2021 |
| FY2018 | Dec 31, 2017 | $4.4K | Mar 26, 2019 |
| FY2017 | Dec 31, 2015 | $15.9K | Mar 23, 2018 |
| FY2016 | Dec 31, 2014 | $35.5K | Mar 24, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.34M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $8.16M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $9.28M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $31.35M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $11.80M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $10.39M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $468.9K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $642.1K | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $490.2K | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $610.2K | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.52M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.11M | Apr 15, 2026 |
| FY2022 | Dec 31, 2022 | $4.75M | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | $7.44M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $825.0K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $2.04M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.66M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $811.3K | Mar 26, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.83M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $5.05M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $5.76M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $26.60M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.36M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $9.57M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($1.57M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | ($1.02M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | ($321.1K) | Mar 24, 2020 |
| FY2018 | Dec 31, 2016 | $240.4K | Mar 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($150.82M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($129.36M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($104.36M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($78.40M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($64.38M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($45.81M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($42.85M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($40.48M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($37.92M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($35.75M) | Mar 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.09M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $5.51M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $6.45M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.61M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $11.42M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $9.88M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $283.3K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $259.7K | Mar 24, 2020 |
| FY2019 | Dec 31, 2017 | $312.7K | Mar 24, 2020 |
| FY2018 | Dec 31, 2016 | $454.0K | Mar 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (22) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (120) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (14) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 23, 2023 |
| FY2015 | Dec 31, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Sep 30, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Jun 30, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Mar 31, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 16, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.73M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 421,475 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 1.98M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 1.76M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 6.38M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 3.83M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 14,992 | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 219 | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | 106.74M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | 55.24M | Mar 23, 2018 |